Details

Autor(en) / Beteiligte

• Parlow, Simon
• Santo, Pietro Di
• Sterling, Lee H.
• Goodliffe, Laura
• Motazedian, Pouya
• Prosperi-Porta, Graeme
• Morgan, Baylie
• Koopman, Zandra
• Jung, Richard G.
• Lepage-Ratte, Melissa Fay
• Robinson, Lisa
• Feagan, Hannah
• Simard, Trevor
• Wells, George A.
• Kyeremanteng, Kwadwo
• Ainsworth, Craig
• Amin, Faizan
• Marbach, Jeffrey A.
• Fernando, Shannon M.
• Labinaz, Marino
• Belley-Cote, Emilie P.
• Hibbert, Benjamin
• Mathew, Rebecca

Titel

Inotrope versus placebo therapy in cardiogenic shock: Rationale and study design of the CAPITAL DOREMI2 trial

Ist Teil von

• The American heart journal, 2023-08, Vol.262, p.83-89

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2023

Quelle

MEDLINE

Beschreibungen/Notizen

• Cardiogenic shock (CS) is a state of end-organ hypoperfusion related to cardiac dysfunction. Current guidelines recommend consideration of inotrope therapy in patients with CS, however no robust data support their use. The purpose of the CAPITAL DOREMI2 trial is to examine the efficacy and safety of inotrope therapy against placebo in the initial resuscitation of patients with CS. This is a multi-center, double-blind, randomized, placebo-controlled trial comparing single-agent inotrope therapy to placebo in patients with CS. A total of 346 participants with Society for Cardiovascular Angiography and Interventions class C or D CS will be randomized in a 1:1 fashion to inotrope or placebo therapy, which will be administered over a 12-hour period. After this period, participants will continue open-label therapies at the discretion of the treating team. The primary outcome is a composite of all-cause in-hospital death, and, as measured during the 12-hour intervention period, any of: sustained hypotension or high dose vasopressor requirements, lactate greater than 3.5 mmol/L at 6 hours or thereafter, need for mechanical circulatory support, arrhythmia leading to emergent electrical cardioversion, and resuscitated cardiac arrest. All participants will be followed for the duration of their hospitalization, and secondary outcomes will be assessed at the time of discharge. This trial will be the first to establish the safety and efficacy of inotrope therapy against placebo in a population of patients with CS and has the potential to alter the standard care provided to this group of patients.